Alector to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced management participation in a virtual fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced management participation in a virtual fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. ET. The live webcast can be accessed on Alector's Investors page, with a replay available for 30 days post-event. Alector's approach targets immune dysfunction in neurodegenerative diseases, specifically in frontotemporal dementia and Alzheimer's disease, aiming to repair genetic mutations affecting the brain's immune response.
Details
News Market Reaction – ALEC
The recorded move for ALEC in the trading session of this news was -0.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of management will participate in a virtual fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020, at 3:50 p.m. ET.
A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 30 days following the event.
About Alector
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Source: Alector, Inc.
Contacts
Media:
1AB
Dan Budwick, 973-271-6085
dan@1abmedia.com
or
Investors:
Alector, Inc.
ir@alector.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.